Ibtehal Makki1, Nouf Alnoon1, Najma Rahmani1, Jawaher Almulla1, Asma Alamiri1, Aisha Alfalasi1, Marwan Zidan2.
Abstract
OBJECTIVE: The objective of this study is to evaluate the impact of the COVID-19 lockdown on glycemic control and accompanying laboratory parameters in patients with type 2 Diabetes Mellitus.
METHODS: This study is a retrospective cohort study that was done on a multicenter level. It was conducted during the lockdown in 341 individuals. HbA1c was tested to measure glycemic control immediately before and after the lockdown period that lasted for 13 weeks.
RESULTS: The primary outcome was the improvement of mean HbA1C after 13 weeks of lockdown compared to the pre-lockdown HbA1C. It was found that the mean HbA1C improved from 7.5±1.5 to 7.3±1.5 with a p-value of 0.001.
CONCLUSION: Our study showed that patients with type 2 diabetes mellitus exhibited an improvement in their glycemic control after the period of lockdown. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
OBJECTIVE: The objective of this study is to evaluate the impact of the COVID-19 lockdown on glycemic control and accompanying laboratory parameters in patients with type 2 Diabetes Mellitus.
METHODS: This study is a retrospective cohort study that was done on a multicenter level. It was conducted during the lockdown in 341 individuals. HbA1c was tested to measure glycemic control immediately before and after the lockdown period that lasted for 13 weeks.
RESULTS: The primary outcome was the improvement of mean HbA1C after 13 weeks of lockdown compared to the pre-lockdown HbA1C. It was found that the mean HbA1C improved from 7.5±1.5 to 7.3±1.5 with a p-value of 0.001.
CONCLUSION: Our study showed that patients with type 2 diabetes mellitus exhibited an improvement in their glycemic control after the period of lockdown. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Entities:
Keywords:
Covid-19; HbA1C; diabetes; lifestyle modifications; lockdown; type 2 diabetes
Mesh：
Substances：
Year: 2022
PMID： 34879807 DOI： 10.2174/1573399818666211208102729
Source DB: PubMed Journal: Curr Diabetes Rev ISSN： 1573-3998